Penumbra, Inc last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $410.1 million (+15.6% year over year) and diluted EPS of $1.07. It usually reports 15–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 14, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 15, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 15–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
410
+15.6%
|
42
-7.8%
|
1.07
-8.5%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
390
+14.9%
|
35
-23.1%
|
0.88
-23.5%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
375
+15.6%
|
33
-16.9%
|
0.82
-18.0%
|
|
Jan 15, 2026
15 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
385
+22.1%
|
47
+40.6%
|
1.20
+46.0%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
355
+17.8%
|
46
+55.3%
|
1.17
+56.0%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
339
+13.4%
|
45
+175.2%
|
1.15
+174.2%
|
|
Apr 23, 2025
23 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
324
+16.3%
|
39
+256.5%
|
1.00
+257.1%
|
|
Feb 18, 2025
49 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
316
+10.8%
|
34
-37.9%
|
0.82
-40.4%
|
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PEN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1321732
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.